Dexpramipexole Dihydrochloride

Phase 3Small molecule

AAreteia Therapeutics

Dexpramipexole Dihydrochloride is one of 35 small molecule programs targeting COPD. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COPDActive, not recruiting

AsthmaTerminated

COPDPhase 2

Active, not recruiting

AsthmaPhase 3

Terminated

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Dexpramipexole Dihydrochloride

AAreteia Therapeutics

Phase 3

3 2

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 3

DUPIXENT

Regeneron

Preclinical

1 4

Atrovent

Boehringer Ingelheim

Preclinical

2 5

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 6

Ozone

TTanta University

Preclinical

1 7

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

1 8

Guanidine Hydrochloride

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Rhinovirus

UUniversity of Virginia

Preclinical

2 10

Spiriva

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma3 trials

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

Terminated·AAreteia Therapeutics·Phase 3·NCT05763121·1,061 enrolled

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

Active, not recruiting·AAreteia Therapeutics·Phase 3·NCT05748600·600 enrolled

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

Terminated·AAreteia Therapeutics·Phase 3·NCT05813288·654 enrolled

Phase II1 trial

Phase III Long-Term Extension Study With Dexpramipexole

Terminated·AAreteia Therapeutics·Phase 3·NCT06388889·509 enrolled

COPD1 trial

A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

Active, not recruiting·AAreteia Therapeutics·Phase 2·NCT06533553·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Dexpramipexole Dihydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexpramipexole Dihydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexpramipexole Dihydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Areteia Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAreteia Therapeutics

Dexpramipexole Dihydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma3 trials

Phase II1 trial

COPD1 trial

References

Drug Info

Quick Facts

Related News